Next Generation Nuclear Medicine

Next Generation Nuclear Medicine: Powering the Future of Precision Health In this episode of ARCS Cognitio, ARCS Australia CEO Tim Boyle leads a compelling conversation on the rapidly evolving world of next-generation nuclear medicines — where physics meets biology to transform how we diagnose and treat disease. Joined by a panel of industry leaders — Christian Behrenbruch (Telix Pharmaceuticals), David James (formerly Sirtex Medical and OncoSil), Rosanne Robinson (Clarity Pharmaceuticals, ex ANSTO, and Cylotek), and Brad Walsh (Glytherix) — the discussion explores the technologies, supply chain challenges, and investment opportunities shaping the future of this dynamic sector. From emerging isotopes and theranostics to Australia’s unique position as a regional hub for radiopharmaceutical innovation, this episode offers deep insights into one of the most exciting frontiers in modern medicine. Tune in to discover how collaboration, capability, and clinical excellence are driving the next era of nuclear medicine — and how Australia can lead the charge. 🎧 Listen now and join the conversation at arcs.com.au.